வில்லியம் லுட்லாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Message :
Required fields
NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to MYCAPSSA
®. The data were shared as an oral presentation at the 30
th Annual American Association of Clinical Endocrinology (AACE) Meeting being held virtually from May 26-29, 2021.
“The encouraging PROs data from the MPOWERED study further our understanding of the potential positive clinical impact that MYCAPSSA has for patients with acromegaly,” said Nienke Biermasz, M.D., Ph.D., Presenting Author. “These PROs provide important information to help physicians assess disease and treatment burden for patients treated with iSSAs and ....

United States , Patrick Bursey , William Ludlam , Ashley Robinson , Nienke Biermasz , Lifesci Advisors , Chiasma Inc , Affairs Of Chiasma , Exchange Commission , Health Problem , American Association Of Clinical Endocrinology , Lifesci Communications , European Union , Corporate Communications , Clinical Development , Annual American Association , Clinical Endocrinology , Work Productivity , Activity Impairment Questionnaire , Specific Health Problem , Vice President , Medical Affairs , Important Safety Information , Prescribing Information , Transient Permeability Enhancer , Private Securities Litigation Reform Act ,